|
Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders
|
Nov 2012
|
Immunobiology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Etiology and survival of aplastic anemia: a study based on clinical investigation
|
Nov 2012
|
J Clin Lab Anal
|
aplastic anemia
|
|
Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies
|
Oct 2012
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
|
Reduced ribosomal RNA expression and increased ribosomal DNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes
|
Oct 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Last Marrow Standing: Bone Marrow Transplantation for Acquired Bone Marrow Failure Conditions
|
Oct 2012
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndrome hematopoietic stem cell
|
Oct 2012
|
Int J Cancer
|
myelodysplastic syndromes (MDS)
|
|
Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab
|
Oct 2012
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Overview of myelodysplastic syndromes
|
Oct 2012
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update
|
Oct 2012
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
|
Oct 2012
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
